Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

Monica Merito, Paolo Giorgi Rossi, Jessica Mantovani, Filippo Curtale, Piero Borgia, Gabriella Guasticchi

Research output: Contribution to journalArticle

Abstract

Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.

Original languageEnglish
Pages (from-to)458-465
Number of pages8
JournalVaccine
Volume25
Issue number3
DOIs
Publication statusPublished - Jan 5 2007

Keywords

  • Cost-effectiveness analysis
  • Elderly
  • Pneumococcal polysaccharide vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Fingerprint Dive into the research topics of 'Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy'. Together they form a unique fingerprint.

  • Cite this